TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 396111

Group type: EXPERIMENTAL
Intervention: Alprenolol (200 mg twice daily for 8 weeks)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 31619160

Group type: EXPERIMENTAL
Intervention: Ampakine CX516
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: PPVT-III
Number of subjects: 42
Study: 28112533

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention
Number of subjects: 3052

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 3052

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3052
Study: 25591723

Group type: EXPERIMENTAL
Intervention: Second pulmonary vein isolation (PVI) procedure (group I, 48 pts)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Antiarrhythmic medication (group II, 46 pts)
Number of subjects: 124
Study: 24256171

Group type: EXPERIMENTAL
Intervention: Manual therapy
Number of subjects: 182

Group type: COMPARATOR
Intervention: Usual care by general practitioner
Number of subjects: 182
Study: 19925617

Group type: EXPERIMENTAL
Intervention: Liraglutide (1.2 mg and 1.8 mg once-daily) plus OADs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Liraglutide (1.2 mg and 1.8 mg once-daily) plus metformin or metformin plus rosiglitazone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Liraglutide (1.2 mg and 1.8 mg once-daily) plus glimepiride
Number of subjects: 0
Study: 19085384

Group type: EXPERIMENTAL
Intervention: Copaxone (glatiramer acetate) 20 mg weekly subcutaneous injections for 12 weeks
Number of subjects: 8

Group type: COMPARATOR
Intervention: Sham injections
Number of subjects: 8
Study: 16816306

Group type: EXPERIMENTAL
Intervention: Generic mental health nurse care
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: Nurse problem-solving treatment
Number of subjects: 247

Group type: COMPARATOR
Intervention: Usual GP care
Number of subjects: 247
Study: 14710057

Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine with epinephrine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Normal saline solution placebo with epinephrine
Number of subjects: 20
Study: 10755058

Group type: EXPERIMENTAL
Intervention: Tryptophan-free amino acid drink
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control drink
Number of subjects: 39
Study: 7868327

Group type: EXPERIMENTAL
Intervention: Skin temperature biofeedback with autogenic training
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Autogenic training only
Number of subjects: 30

Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 30
Study: 2035325

Group type: EXPERIMENTAL
Intervention: 1 mg peroral vitamin K
Number of subjects: 300

Group type: COMPARATOR
Intervention: 1 mg intramuscular vitamin K
Number of subjects: 300
Study: 7016626

Group type: EXPERIMENTAL
Intervention: Trimethoprim 200 mg x 2 for 10 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nitrofurantoin 50 mg x 4 for 10 days
Number of subjects: 0
Study: 31096941

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (healthy diet and increased physical activity)
Number of subjects: 260

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 260
Study: 28701602

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (1 mcg/kg) over 10 min before propofol (1 mg/kg)
Number of subjects: 500

Group type: COMPARATOR
Intervention: Propofol (1 mg/kg) only
Number of subjects: 500
Study: 25791716

Group type: EXPERIMENTAL
Intervention: Endovascular therapy
Number of subjects: 185

Group type: COMPARATOR
Intervention: Intravenous tissue-type plasminogen activator
Number of subjects: 185
Study: 23398953

Group type: EXPERIMENTAL
Intervention: Fish oil-based lipid emulsion (FOLE) (Omegaven(®))
Number of subjects: 63

Group type: COMPARATOR
Intervention: Control lipid emulsion (MCT/LCT; Lipovenos MCT(®))
Number of subjects: 63
Study: 20861241

Group type: EXPERIMENTAL
Intervention: Adjustable Stimulation (AS)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Preset Stimulation (PS)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Medical Management (MM)
Number of subjects: 110
Study: 19725966

Group type: EXPERIMENTAL
Intervention: Artesunate monotherapy
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Artesunate-mefloquine combination therapy
Number of subjects: 91

Group type: COMPARATOR
Intervention: Non-febrile healthy controls
Number of subjects: 91
Study: 17541696

Group type: EXPERIMENTAL
Intervention: Ketamine
Number of subjects: 3

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3
Study: 15093200

Group type: EXPERIMENTAL
Intervention: Concomitant chemotherapy and radiation therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sequential treatment with chemotherapy first followed by radiation
Number of subjects: 0
Study: 11918235

Group type: EXPERIMENTAL
Intervention: Subtotal resection with contralateral hemithyroidectomy (SHT)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Subtotal resection on both sides (STT)
Number of subjects: 152
Study: 9917601

Group type: EXPERIMENTAL
Intervention: Femoral head diameter of 22 mm with acetabular component outer diameter of 56 mm or larger
Number of subjects: 338

Group type: EXPERIMENTAL
Intervention: Femoral head diameter of 28 mm with acetabular component outer diameter of 62 mm or larger
Number of subjects: 338

Group type: COMPARATOR
Intervention: Femoral head diameter of 28 mm with acetabular component outer diameter of 60 mm or smaller
Number of subjects: 338
Study: 7852615

Group type: EXPERIMENTAL
Intervention: Plax (Colgate) prebrushing rinse
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo solution
Number of subjects: 19
Study: 2901270

Group type: EXPERIMENTAL
Intervention: Vecuronium 0.3 mg kg‐1
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pancuronium 0.1 mg kg‐1
Number of subjects: 0
Study: 31990700

Group type: EXPERIMENTAL
Intervention: Lesional skin
Number of subjects: 48

Group type: COMPARATOR
Intervention: Perilesional normal skin
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Electron microscopy
Number of subjects: 48
Study: 29474602

Group type: EXPERIMENTAL
Intervention: Haemodialysis patients with BTP concentration >7.96 mg/L
Number of subjects: 3869

Group type: EXPERIMENTAL
Intervention: Coronary angiography patients with BTP concentration >0.67 mg/L
Number of subjects: 3869
Study: 26707677

Group type: EXPERIMENTAL
Intervention: Divergent thinking assessed by the alternative-uses-task (AUT)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Convergent thinking assessed by the Intelligenz-Struktur-Test-2000 (IST)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Sensorimotor adaptation assessed by a pointing task with 60° rotated visual feedback
Number of subjects: 49
Study: 25563312

Group type: EXPERIMENTAL
Intervention: Oral ganciclovir (GCV) 1000 mg 3 times per day for 8 weeks, plus topical 0.15% GCV ophthalmic gel and 0.1% fluorometholone eye drops.
Number of subjects: 173

Group type: COMPARATOR
Intervention: Topical acyclovir (ACV) with the same ophthalmic gel and eye drops, plus oral ACV 400 mg 5 times a day for 10 weeks, then 400 mg 2 times per day for 6 months.
Number of subjects: 173

Group type: COMPARATOR
Intervention: Negative control (placebo) group with topical 0.15% GCV ophthalmic gel and 0.1% fluorometholone eye drops.
Number of subjects: 173
Study: 23761134

Group type: EXPERIMENTAL
Intervention: Postmeal walking for 15 min
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Sustained morning walking for 45 min
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control day (no walking)
Number of subjects: 10
Study: 21168907

Group type: EXPERIMENTAL
Intervention: Tetric EvoCeram
Number of subjects: 28

Group type: COMPARATOR
Intervention: Filtek Z250 (Control)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Filtek Supreme
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Admira (Ormocer)
Number of subjects: 28
Study: 18439113

Group type: COMPARATOR
Intervention: Tianeptine
Number of subjects: 21

Group type: COMPARATOR
Intervention: Methylphenidate
Number of subjects: 21

Group type: COMPARATOR
Intervention: Risperidone
Number of subjects: 21

Group type: COMPARATOR
Intervention: Clonidine
Number of subjects: 21

Group type: COMPARATOR
Intervention: Naltrexone
Number of subjects: 21
Study: 17142146

Group type: COMPARATOR
Intervention: ezetimibe 10 mg daily with placebo colesevelam HCl twice daily (E)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: ezetimibe 10 mg daily with 1.875 g colesevelam HCl twice daily (E + C)
Number of subjects: 20
Study: 12663600

Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg (A10)
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg (A80)
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Atorvastatin treatment
Number of subjects: 217

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 217
Study: 10873879

Group type: EXPERIMENTAL
Intervention: 8-L exchanges
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: 6-L exchanges
Number of subjects: 82

Group type: COMPARATOR
Intervention: Control group (3 daily 2-L exchanges)
Number of subjects: 82
Study: 9110103

Group type: EXPERIMENTAL
Intervention: meta‐chlorophenylpiperazine (m‐CPP)
Number of subjects: 10

Group type: COMPARATOR
Intervention: identical placebo capsules
Number of subjects: 10
Study: 8249364

Group type: EXPERIMENTAL
Intervention: Subcutaneous recombinant human erythropoietin (rhEpo) 6 x 10,000 U administered 4 and 2 weeks before surgery
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control group (no rhEpo)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Subcutaneous recombinant human erythropoietin (rhEpo)
Number of subjects: 49
Study: 3900456

Group type: EXPERIMENTAL
Intervention: TMS-19-Q.GC tablet (TMS) at a dosage of 600 mg daily
Number of subjects: 218

Group type: COMPARATOR
Intervention: Midecamycin (MDM) at a dosage of 1200 mg daily
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: TMS-19-Q.GC tablet (TMS)
Number of subjects: 218

Group type: COMPARATOR
Intervention: Midecamycin (MDM)
Number of subjects: 218
Study: 31846475

Group type: EXPERIMENTAL
Intervention: COR-1 (1 mg DNA administered intradermally as two injections of 500 μg each)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo (administered intradermally as two injections of 500 μg each)
Number of subjects: 44
Study: 29431027

Group type: EXPERIMENTAL
Intervention: Sheng-Yu-Tang (Chinese herbal formula) for up to 6 months
Number of subjects: 18

Group type: COMPARATOR
Intervention: Standard-care treatment administered by their oncologist
Number of subjects: 18
Study: 25901734

Group type: EXPERIMENTAL
Intervention: F2R rs168753 minor allele
Number of subjects: 503

Group type: EXPERIMENTAL
Intervention: P2RY12 rs6809699 minor allele
Number of subjects: 503
Study: 24189254

Group type: EXPERIMENTAL
Intervention: 1.0 mg/kg single-dose primaquine (PMQ)
Number of subjects: 28

Group type: COMPARATOR
Intervention: 0.5 mg/kg daily for 14 days
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: 1.0 mg/kg twice daily
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: 1.0 mg/kg 7-day PMQ regimen
Number of subjects: 28
Study: 22922489

Group type: EXPERIMENTAL
Intervention: Imatinib mesylate (IM) therapy in early chronic phase (ECP)
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Imatinib mesylate (IM) therapy in late chronic phase (LCP)
Number of subjects: 189

Group type: COMPARATOR
Intervention: Interferon (IFN)‐alpha‐2 followed by crossover to IM in late chronic phase (LCP)
Number of subjects: 189
Study: 20799042

Group type: EXPERIMENTAL
Intervention: Usual endurance training supplemented with heavy strength training twice a week during a 12-week preparatory period followed by strength maintenance training once a week during the first 13 weeks of a competition period (E + S)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Usual endurance training during the whole intervention period (E)
Number of subjects: 12
Study: 18003562

Group type: EXPERIMENTAL
Intervention: Insomnia medication (verum)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 0
Study: 16331754

Group type: EXPERIMENTAL
Intervention: Pegsunercept 800 microg/kg
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Pegsunercept 400 microg/kg
Number of subjects: 194

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 194
Study: 17642022

Group type: EXPERIMENTAL
Intervention: Structured, individualized education on pressure ulcer prevention (4 hours)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Standard education (control group)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Both groups (intervention and control)
Number of subjects: 41
Study: 9467549

Group type: EXPERIMENTAL
Intervention: Transdermal estradiol (E2; 0.1 mg every 3.5 days; n = 48)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Oral conjugated equine estrogens (1.25 mg every day; n = 49)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Transdermal estradiol (E2)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Oral conjugated equine estrogens
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Transdermal estradiol (E2) and Oral conjugated equine estrogens
Number of subjects: 97
Study: 7894856

Group type: EXPERIMENTAL
Intervention: Calibrated GHQ
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: CES-D
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: CIDI
Number of subjects: 1000
Study: 2650011

Group type: EXPERIMENTAL
Intervention: Supplemental oxygen
Number of subjects: 23

Group type: COMPARATOR
Intervention: Compressed air
Number of subjects: 23
Study: 30099716

Group type: EXPERIMENTAL
Intervention: FOB‐PDT (fibre optic bronchoscopy-guided percutaneous dilatational tracheostomy)
Number of subjects: 90

Group type: COMPARATOR
Intervention: PDT (percutaneous dilatational tracheostomy)
Number of subjects: 90
Study: 28926415

Group type: EXPERIMENTAL
Intervention: Raloxifene
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Baseline confrontation naming
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Category fluency
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Semantic recognition
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Composite of semantic recognition and semantic naming
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Semantic-lexical retrieval factor
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Baseline semantic memory tests
Number of subjects: 42
Study: 26141837

Group type: EXPERIMENTAL
Intervention: Denosumab
Number of subjects: 98

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study: 23302662

Group type: EXPERIMENTAL
Intervention: Dietary pattern with high loading values of vegetables and vegetable oils
Number of subjects: 2031

Group type: EXPERIMENTAL
Intervention: Dietary pattern reflecting a high n-6:n-3 fatty acid intake ratio
Number of subjects: 2031
Study: 21679511

Group type: EXPERIMENTAL
Intervention: 1 mg/kg intravenous methylprednisolone
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 3 mg/kg intravenous methylprednisolone
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no steroids)
Number of subjects: 40
Study: 18295436

Group type: EXPERIMENTAL
Intervention: Integrated cognitive-behavioral therapy (ICBT)
Number of subjects: 197

Group type: COMPARATOR
Intervention: Twelve-step facilitation
Number of subjects: 197
Study: 16632012

Group type: EXPERIMENTAL
Intervention: High-hemoglobin group (target 13 to 15 g/dL)
Number of subjects: 195

Group type: COMPARATOR
Intervention: Low-hemoglobin group (target 11 to 12 g/dL)
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: High-hemoglobin group
Number of subjects: 195

Group type: COMPARATOR
Intervention: Low-hemoglobin group
Number of subjects: 195
Study: 14669415

Group type: EXPERIMENTAL
Intervention: Hysteroscopic metroplasty
Number of subjects: 31

Group type: COMPARATOR
Intervention: Strassman's operation
Number of subjects: 31
Study: 10953488

Group type: EXPERIMENTAL
Intervention: Hysteroscopic polypectomy
Number of subjects: 181

Group type: COMPARATOR
Intervention: Fractional curettage
Number of subjects: 181
Study: 8995474

Group type: EXPERIMENTAL
Intervention: iomeprol 300 mg I/ml
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: iomeprol 400 mg I/ml
Number of subjects: 20
Study: 1638251

Group type: EXPERIMENTAL
Intervention: Fixed appointments with option to change time
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: Fixed appointments requiring telephoned confirmation of intention to attend
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: Open invitations inviting recipient to telephone to make an appointment
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: All methods
Number of subjects: 1200
Study: 6387210

Group type: EXPERIMENTAL
Intervention: Sustained release propranolol (LA)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Conventional propranolol (Prop)
Number of subjects: 10
Study: 30139835

Group type: EXPERIMENTAL
Intervention: Erlotinib plus Tivantinib (T+E)
Number of subjects: 996

Group type: COMPARATOR
Intervention: Erlotinib plus Placebo (P+E)
Number of subjects: 996
Study: 28092139

Group type: EXPERIMENTAL
Intervention: Physiotherapy (PT)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Occupational Therapy (OT)
Number of subjects: 46
Study: 26333375

Group type: EXPERIMENTAL
Intervention: Bioresorbable polymer sirolimus-eluting stent (BP-SES)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Permanent polymer everolimus-eluting stent (PP-EES)
Number of subjects: 36
Study: 22897595

Group type: EXPERIMENTAL
Intervention: Cantharidin
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 22115704

Group type: EXPERIMENTAL
Intervention: pemetrexed-cisplatin
Number of subjects: 3467

Group type: COMPARATOR
Intervention: gemcitabine-cisplatin
Number of subjects: 3467
Study: 20662805

Group type: EXPERIMENTAL
Intervention: Baclofen 30 mg/d
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 17699309

Group type: EXPERIMENTAL
Intervention: Cyclosporine
Number of subjects: 75

Group type: COMPARATOR
Intervention: Azathioprine
Number of subjects: 75
Study: 14583363

Group type: EXPERIMENTAL
Intervention: Bail-out stenting after unsuccessful balloon angioplasty
Number of subjects: 1044

Group type: COMPARATOR
Intervention: Routine stenting
Number of subjects: 1044

Group type: COMPARATOR
Intervention: Successful balloon angioplasty
Number of subjects: 1044
Study: 10878704

Group type: EXPERIMENTAL
Intervention: Stress echocardiography
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Stress echocardiography in hypertensive group
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Stress echocardiography in normotensive group
Number of subjects: 173
Study: 9364675

Group type: EXPERIMENTAL
Intervention: S-L* (yeast-derived recombinant hepatitis B virus vaccine containing surface antigen and selected preS1 and preS2 sequences)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Engerix-B (vaccine containing surface antigen alone)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Both S-L* and Engerix-B
Number of subjects: 32
Study: 1424027

Group type: EXPERIMENTAL
Intervention: Normothermic antegrade blood cardioplegia (n = 25)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Normothermic retrograde blood cardioplegia (n = 23)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Intermittent cold antegrade blood cardioplegia (n = 26)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Warm antegrade cardioplegia
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Warm retrograde cardioplegia
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Cold cardioplegia
Number of subjects: 74
Study: 4065106

Group type: EXPERIMENTAL
Intervention: Domperidone, 10 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Atropine, 0.6 mg (given at peak effect of domperidone)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Atropine, 0.6 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Domperidone (after atropine)
Number of subjects: 10
Study: 31791962

Group type: EXPERIMENTAL
Intervention: Adrenaline
Number of subjects: 150
Study: 29770163

Group type: EXPERIMENTAL
Intervention: PDRN prolotherapy
Number of subjects: 32
Study: 26498973

Group type: EXPERIMENTAL
Intervention: Task‐Specific Checklist
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Global Rating Scale
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Inter-rater and intra-rater reliability
Number of subjects: 3
Study: 24767265

Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Healthy Topics (HT)
Number of subjects: 43
Study: 22453754

Group type: EXPERIMENTAL
Intervention: Exemestane
Number of subjects: 2754

Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 2754
Study: 21124125

Group type: EXPERIMENTAL
Intervention: Acellular cadaveric dermis (AlloDerm)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Native subpectoral capsule (internal control)
Number of subjects: 20
Study: 17545350

Group type: EXPERIMENTAL
Intervention: Computerised decision aid
Number of subjects: 109

Group type: COMPARATOR
Intervention: Guidelines arm (Control)
Number of subjects: 109
Study: 17015999

Group type: EXPERIMENTAL
Intervention: Sulbactam/ampicillin therapy (6 g/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Imipenem/cilastatin therapy (1 g/day)
Number of subjects: 0
Study: 12787040

Group type: EXPERIMENTAL
Intervention: OSF mucosa
Number of subjects: 59

Group type: COMPARATOR
Intervention: Normal oral mucosa (NOM)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Friction hyperkeratosis on OSF buccal mucosa (FHOSF)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Oral leukoplakia on OSF buccal mucosa (OLOSF)
Number of subjects: 59
Study: 11015032

Group type: EXPERIMENTAL
Intervention: Zolpidem 8.03 mg
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Zolpidem 16.06 mg
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Promethazine 50 mg
Number of subjects: 192

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 192
Study: 9382431

Group type: EXPERIMENTAL
Intervention: Fecal occult blood testing (yearly)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Once-in-a-lifetime sigmoidoscopy at 55-60 years of age
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Visual inspection of the oral cavity and pharynx with flexible endoscopy and blue-toluidine staining
Number of subjects: 0
Study: 1420743

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (5 mg by sublingual route 5 min before the meal)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Sublingual nifedipine (20 mg by sublingual route 30 min before the meal)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 11
Study: 3900458

Group type: EXPERIMENTAL
Intervention: TMS-19-Q.GC tablet (600 mg daily)
Number of subjects: 265

Group type: COMPARATOR
Intervention: Josamycin (1,200 mg daily)
Number of subjects: 265